Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$39.07 USD
+0.14 (0.36%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $39.10 +0.03 (0.08%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COLL 39.07 +0.14(0.36%)
Will COLL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Other News for COLL
Insider Sale: EVP and Chief Medical Officer Thomas Smith Sells 9,593 Shares of Collegium ...
IHF: Healthcare Dashboard For September
Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 20,225 Shares of Collegium ...
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical